MiniMed Go app; Simplera sensor
Medtronic Minimed · Decision date Jan 23, 2026
What did the FDA approve?
FDA records P160007/S058 as a supplement to PMA P160007, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jan 23, 2026.
FDA approval order statement
for a predetermined change control plan (PCCP) regarding alternate primary user interfaces and maintaining compatibility with alternate display devices.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Clinical Chemistry
- Decision date
- Jan 23, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P160007/S058
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Minimed
- Product code
- MDS
- Decision code
- APPR
- Decision date
- Jan 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Sensor, glucose, invasive.
- Applicant
- Medtronic Minimed
- Product code
- MDS
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P160007/S053 · Related supplement
Guardian Connect system
P160007/S055 · Related supplement
Simplera System
P160007/S054 · Related supplement
Guardian Connect System
P160007/S056 · Related supplement
Guardian Connect System Simplera System
P160007/S058 received
Application receipt date recorded by FDA.
P160007/S057 · Related supplement
Simplera System
P160007/S059 · Related supplement
Simplera System
P160007/S058 · FDA decision
Real-Time Process
P160007/S062 · Related supplement
Simplera and Simplera Sync
P160007/S060 · Related supplement
Simplera system
P160007/S063 · Related supplement
Simplera System; Simplera Sync
Timeline entries are records held by MedtechLedger for P160007. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160007
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Guardian Connect systemP160007/S053 | Medtronic Minimed | PMA supplement | Aug 25, 2025 | FDA |
Simplera SystemP160007/S055 | Medtronic Minimed | PMA supplement | Sep 12, 2025 | FDA |
Guardian Connect SystemP160007/S054 | Medtronic Minimed | PMA supplement | Oct 9, 2025 | FDA |
Guardian Connect System Simplera SystemP160007/S056 | Medtronic Minimed | PMA supplement | Oct 16, 2025 | FDA |
Simplera SystemP160007/S057 | Medtronic Minimed | PMA supplement | Dec 5, 2025 | FDA |
Simplera SystemP160007/S059 | Medtronic Minimed | PMA supplement | Dec 8, 2025 | FDA |
Simplera and Simplera SyncP160007/S062 | Medtronic Minimed | PMA supplement | May 26, 2026 | FDA |
Simplera systemP160007/S060 | Medtronic Minimed | PMA supplement | Jun 12, 2026 | FDA |
Simplera System; Simplera SyncP160007/S063 | Medtronic Minimed | PMA supplement | Jul 21, 2026 | FDA |
Explore the linked device profile
Other records with product code MDS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Diabetes Care, Inc. | PMA supplement | Sep 1, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Minimed
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 18000 Devonshire St., Northridge, CA, 91325
Sources and methodology
- Original FDA record: P160007/S058
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





